dc.contributor.author | Omosa-Manyonyi, Gloria S. | |
dc.contributor.author | Omu Anzala, Walter Jaoko | |
dc.contributor.author | Ogutu, Hilda | |
dc.contributor.author | Wakasiaka, Sabina | |
dc.contributor.author | Malogo, Roselyn | |
dc.contributor.author | Nyange, Jacqueline | |
dc.contributor.author | Njuguna, Pamela | |
dc.contributor.author | Ndinya-Achola, JO | |
dc.contributor.author | Bhatt, Kirana | |
dc.contributor.author | Bashir, Farah | |
dc.contributor.author | Oyaro, Micah | |
dc.contributor.author | Schmidt, Claudia | |
dc.contributor.author | Priddy, Frances | |
dc.contributor.author | Fast, Patricia | |
dc.date.accessioned | 2013-02-21T08:20:46Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | PLoS ONE | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/10567 | |
dc.description.abstract | With the persistent challenges towards controlling the HIV epidemic, there is an ongoing need for research
into HIV vaccines and drugs. Sub-Saharan African countries - worst affected by the HIV pandemic - have participated in the
conduct of clinical trials for HIV vaccines. In Kenya, the Kenya AIDS Vaccine Initiative (KAVI) at the University of Nairobi has
conducted HIV vaccine clinical trials since 2001 | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Volume 6 Issue 1; | |
dc.subject | Aids Vaccine Initiative | en |
dc.title | Reasons for Ineligibility in phase 1 and 2A HIV Vaccine Initiative (KAVI), Kenya | en |
dc.type | Article | en |
local.embargo.terms | 6 months | en |
local.embargo.lift | 2013-08-20T08:20:46Z | |
local.publisher | School of nursing science, University of Nairobi | en |